Akoya Biosciences and NeraCare announced an exclusive agreement under which the parties will develop market opportunities for combining Akoya’s PhenoImager HT platform and NeraCare’s Immunoprint assay for patient stratification and therapy selection in early-stage melanoma patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
- Akoya Biosciences opens Operations and Manufacturing Center in Marlborough
- Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
- Akoya, Shanghai KR announce KR-HT5 receive premarket approval from China’s NMPA
- Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024